BCM
SGMO

Brookstone Capital Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Brookstone Capital Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-500
Closed -$3K – 754
2015
Q3 		$3K Hold
500
– – ﹤0.01% 1625
2015
Q2 		$6K Buy
+500
New +$6.45K ﹤0.01% 1427

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Brookstone Capital Management's SGMO Position: Q4 2015 in Review

Brookstone Capital Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2015, closing a stake of 500 shares — an estimated $3K sold.

Brookstone Capital Management first reported a position in SGMO in Q2 2015 and held it in 2 quarters. The position peaked at $6K in Q2 2015. 141 funds tracked by Wall St. Rank hold SGMO as of Q4 2015.

  • Brookstone Capital Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2015 after selling out during the quarter.
  • Brookstone Capital Management sold 500 SANGAMO THERAPEUTICS INC shares in Q4 2015, an estimated $3K.
  • Brookstone Capital Management first reported a position in SANGAMO THERAPEUTICS INC in Q2 2015 and held it in 2 quarters.
  • Brookstone Capital Management's SANGAMO THERAPEUTICS INC position peaked at $6K in Q2 2015.
  • 141 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2015.

Based on Brookstone Capital Management's 13F filing for Q4 2015, filed 14 Jan 2016.